Journals / Turkish Journal of Gastroenterology / 2015 / Cilt: 26 - Sayı: 6

Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in patients with familial Mediterranean fever

Pages
487–491
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, the increased MMP-9 levels observed in FMF patients could rationalize therapeutic targeting to MMPs

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP1) are well-known inflammatory biomarkers, with a diagnostic potential for various diseases.
📊
Key Findings & Data:The aim of the present study was to determine the potential diagnostic applications of serum MMP-9 and TIMP-1 concentrations in patients with familial Mediterranean fever (FMF).
💡
Conclusion & Impact:Thus, the increased MMP-9 levels observed in FMF patients could rationalize therapeutic targeting to MMPs
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: Serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP1) are well-known inflammatory biomarkers, with a diagnostic potential for various diseases. The aim of the present study was to determine the potential diagnostic applications of serum MMP-9 and TIMP-1 concentrations in patients with familial Mediterranean fever (FMF). Materials and Methods: A total of 66 male FMF patients and 40 age-matched healthy subjects were included in this research. TIMP-1 and MMP-9 levels with conventional inflammation markers were determined. Pearson correlation analysis was used to determine the correlation between the characteristics of patients and the laboratory data. Results: In patients with FMF, serum MMP-9 levels and MMP-9/TIMP-1 ratios were found to be significantly elevated in both acute episode and asymptomatic periods (p=0.0001 and p=0.0001, respectively). There was no significant difference between TIMP-1 levels. A significant negative correlation between patients’ current age and TIMP-1 level in patients with acute episodes was detected (p=0.0008, r=−0.52). Moreover, a moderate negative correlation was noticed between erythrocyte sedimentation rate and TIMP-1 level in patients with acute episodes (p=0.01, r=−0.39). Additionally, a moderate negative correlation was found between the duration of colchicine use and MMP-9 and TIMP-1 levels during the attack period (p=0.04, r=−0.36 and p=0.02, r=−0.39, respectively). Conclusion: Our findings demonstrate that a significant MMP-9/TIMP-1 imbalance exists in patients with FMF, which reflects an ongoing inflammation in both FMF periods. Thus, the increased MMP-9 levels observed in FMF patients could rationalize therapeutic targeting to MMPs

🔖

Cite This Article

DİNÇ, M., TANOĞLU, A., YAZGAN, Y., BEYAZIT, Y., ÖNCÜ, K., ÖNEM, Y., HIRA, S., KAPLAN, M., KÜÇÜK, İ., SAKİN, Y. S., DEMİRTÜRK, L. (2015). Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in patients with familial Mediterranean fever. Turkish Journal of Gastroenterology, Cilt: 26 - Sayı: 6, 487–491. https://ajindex.com/articles/409404

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Singh D, Srivastava SK, Chaudhuri TK, Upadhyay G. Multifaceted role of matrix metalloproteinases (MMPs). Front Mol Biosci 2015
  2. [CrossRef] 2. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003
  3. [CrossRef] 3. Ganea E, Trifan M, Laslo AC, Putina G, Cristescu C. Matrix metalloproteinases: useful and deleterious. Biochem Soc Trans 2007
  4. [CrossRef] 4. Apte SS, Parks WC. Matrix metalloproteinases: A parade of functions in matrix biology and an outlook for the future. Matrix Biol 2015
  5. [CrossRef] 5. Pulkoski-Gross AE. Historical perspective of matrix metalloproteases. Front Biosci (Schol Ed) 2015
  6. [CrossRef] 6. Fields GB. New strategies for targeting matrix metalloproteinases. Matrix Biol 2015
  7. [CrossRef] 7. Oncu K, Yazgan Y, Tanoglu A, et al. Can serum fetuin-A be regarded as an inflammatory marker among patients with familial Mediterranean fever? Dig Dis Sci 2013
  8. [CrossRef] 8. Akgul O, Kilic E, Kilic G, Ozgocmen S. Efficacy and safety of biologic treatments in Familial Mediterranean Fever. Am J Med Sci 2013
  9. [CrossRef] 9. Soriano A, Manna R. Familial Mediterranean fever: new phenotypes. Autoimmun Rev 2012
  10. [CrossRef] 10. Ozçakar ZB, Yalçınkaya F. Vascular comorbidities in familial Mediterranean fever. Rheumatol Int 2011
  11. [CrossRef] 11. Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease
  12. the expanding role of NLRP3 inflammasome. Eur J Intern Med 2010
  13. [CrossRef] 12. Ozkurede VU, Franchi L. Immunology in clinic review series
  14. focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol 2012
  15. [CrossRef] 13. Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 2011
  16. [CrossRef] 14. Kiraz S, Ertenli I, Arici M, et al. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol 1998
  17. Ozen S, Bakkaloglu A, Yilmaz E, et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol 2003
  18. Schlesinger M, Ilfeld D, Handzel ZT, et al. Effect of colchicine on immunoregulatory abnormalities in familial Mediterranean fever. Clin Exp Immunol 1983
  19. Liu P, Sun M, Sader S. Matrix